Stocktoria

Eton Pharmaceuticals, Inc. ETON

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-11-09
Chart by TradingView
5/9
Piotroski F — financial health
-2.05
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$80.0M$39.0M$31.6M$21.3M$21.8M
Gross profit$42.7M$23.4M$21.1M$14.3M$19.0M
Operating income-$844,000-$2.6M-$1.2M-$8.3M-$1.5M
Net income-$4.6M-$3.8M-$936,000-$9.0M-$2.0M
Operating cash flow$10.5M$969,000$6.8M$4.8M-$4.7M
Free cash flow$10.2M$943,000$6.8M$4.8M-$4.7M
Total assets$92.1M$76.1M$31.7M$25.0M$27.5M
Total liabilities$66.0M$51.7M$16.3M$12.0M$9.8M
Shareholders' equity$26.2M$24.4M$15.5M$13.1M$17.6M
Ratios
Gross margin53.5%60.0%66.6%67.4%87.1%
Operating margin-1.1%-6.7%-3.8%-38.9%-6.8%
Net margin-5.8%-9.8%-3.0%-42.4%-9.0%
FCF margin12.7%2.4%21.5%22.5%-21.7%
Return on assets-5.0%-5.0%-2.9%-36.0%-7.1%
Return on equity-17.6%-15.7%-6.0%-69.0%-11.1%
Debt / equity0.83×1.22×0.00×0.41×0.30×
Current ratio1.572.061.653.105.18
Revenue growth104.9%23.3%48.9%-2.7%55879.5%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC163,321$4.0M

Why these scores methodology →

Piotroski F-score: 5/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -2.05 (distress)

  • Working capital / assets 0.24
  • Retained earnings / assets -1.221
  • EBIT / assets -0.009
  • Equity / liabilities 0.397

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001710340 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.